Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
$83.61
-4.5%
$94.22
$69.81
▼
$148.83
$7.90B1.36853,150 shs839,983 shs
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
$21.53
$19.41
$5.64
▼
$21.53
$2.22B-1.741.52 million shs2.99 million shs
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
$124.83
-4.7%
$139.88
$77.00
▼
$160.81
$8.77B1.21614,125 shs565,199 shs
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
$107.48
-6.6%
$96.98
$74.50
▼
$122.20
$7.62B2.171.76 million shs947,318 shs
The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
0.00%+2.16%-0.62%-27.46%-20.66%
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
0.00%0.00%0.00%0.00%+144.66%
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
0.00%-0.83%+1.71%-17.44%+54.77%
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
0.00%+2.44%+33.48%-0.36%+15.70%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
$83.61
-4.5%
$94.22
$69.81
▼
$148.83
$7.90B1.36853,150 shs839,983 shs
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
$21.53
$19.41
$5.64
▼
$21.53
$2.22B-1.741.52 million shs2.99 million shs
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
$124.83
-4.7%
$139.88
$77.00
▼
$160.81
$8.77B1.21614,125 shs565,199 shs
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
$107.48
-6.6%
$96.98
$74.50
▼
$122.20
$7.62B2.171.76 million shs947,318 shs
The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
0.00%+2.16%-0.62%-27.46%-20.66%
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
0.00%0.00%0.00%0.00%+144.66%
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
0.00%-0.83%+1.71%-17.44%+54.77%
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
0.00%+2.44%+33.48%-0.36%+15.70%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
2.88
Moderate Buy$155.0085.38% Upside
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
1.89
Reduce$22.836.05% Upside
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
3.06
Buy$166.6733.51% Upside
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
2.77
Moderate Buy$142.0032.12% Upside

Current Analyst Ratings Breakdown

Latest DAWN, PTGX, RYTM, and ABVX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/9/2026
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
Reiterated RatingOutperform
11/6/2026
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
Boost Price TargetBuy$170.00 ➝ $221.00
11/6/2026
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
Lower Price TargetOverweight$145.00 ➝ $142.00
11/5/2026
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
Boost Price TargetBuy$143.00 ➝ $147.00
11/4/2026
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
UpgradeHold (C+) ➝ Buy (B-)
11/4/2026
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
Reiterated RatingMarket Perform
11/4/2026
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
Reiterated RatingOutperform
11/4/2026
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
Boost Price TargetMarket Outperform$160.00 ➝ $166.00
11/3/2026
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
Reiterated RatingBuy
11/3/2026
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
Lower Price TargetBuy$130.00 ➝ $114.00
10/23/2026
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
DowngradeBuy (B-) ➝ Hold (C+)
(Data available from 11/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
N/AN/AN/AN/A$6.57 per shareN/A
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
$158.18M14.06N/AN/A$4.30 per share5.01
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
$46.02M177.05N/AN/A$16.62 per share7.51
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
$189.76M39.27N/AN/A$1.27 per share84.63
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
-$380.27M-$6.06N/AN/AN/AN/A-91.69%-71.96%12/21/2026 (Estimated)
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
-$107.32M-$1.03N/A2,153.00N/A-67.85%-23.43%-20.69%N/A
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
-$130.15M$4.7228.4793.86N/A62.04%42.83%40.29%N/A
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
-$196.54M-$2.90N/AN/AN/A-69.03%-171.16%-43.00%N/A

Latest DAWN, PTGX, RYTM, and ABVX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026Q3 2026
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
$2.50$3.07+$0.57$3.07$238.49 million$274.41 million
11/3/2026Q3 2026
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
-$0.7097-$0.61+$0.0997-$0.61$85.56 million$92.13 million
9/21/2026Q2 2026
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
-$0.9170-$1.71-$0.7930-$1.68$0.80 million$1.37 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
N/AN/AN/AN/AN/A
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
N/AN/AN/AN/AN/A
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
N/AN/AN/AN/AN/A
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
N/A
5.97
5.97
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
N/A
8.02
7.91
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
N/A
19.85
21.71
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
N/A
2.78
2.57

Institutional Ownership

CompanyInstitutional Ownership
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
47.91%
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
87.95%
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
98.63%
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
9887.55 millionN/AOptionable
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
60103.33 million96.93 millionOptionable
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
14165.27 million61.88 millionOptionable
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
41469.33 million65.24 millionOptionable

Recent News About These Companies

Rhythm Pharmaceuticals Earnings Call Signals Strong Growth Ahead

New MarketBeat Followers Over Time

Media Sentiment Over Time

Abivax stock logo

Abivax NASDAQ:ABVX

$83.61 -3.97 (-4.53%)
Closing price 04:00 PM Eastern
Extended Trading
$83.77 +0.16 (+0.19%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

Day One Biopharmaceuticals stock logo

Day One Biopharmaceuticals NASDAQ:DAWN

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

Protagonist Therapeutics stock logo

Protagonist Therapeutics NASDAQ:PTGX

$124.83 -6.12 (-4.67%)
Closing price 04:00 PM Eastern
Extended Trading
$124.50 -0.33 (-0.26%)
As of 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Rhythm Pharmaceuticals stock logo

Rhythm Pharmaceuticals NASDAQ:RYTM

$107.48 -7.54 (-6.56%)
Closing price 04:00 PM Eastern
Extended Trading
$108.50 +1.02 (+0.95%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.